US2020361932A1PendingUtilityA1

Salts and crystalline forms of an apoptosis-inducing agent

74
Assignee: ABBVIE INCPriority: Nov 23, 2010Filed: Jul 31, 2020Published: Nov 19, 2020
Est. expiryNov 23, 2030(~4.4 yrs left)· nominal 20-yr term from priority
C07D 471/04A61K 31/437A61P 35/02A61K 31/496A61P 37/00A61P 35/00A61P 37/06C07B 2200/13A61P 37/02A61P 43/00A61K 31/4375
74
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Salts and crystalline forms of 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}-sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . Solid amorphous 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide (Compound 1). 
     
     
         2 . A process for preparing a pharmaceutical formulation comprising combining the solid amorphous Compound 1 of  claim 1  with a pharmaceutically acceptable excipient.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.